Q2 2023
Released Aug 7, 2023, after the close
10-Q filed Aug 7, 2023, 38 days after period end · 0001628280-23-027772
Q2 2023 · 10-Q
Revenue$0.00$0.00 no prior Q2 2022 on fileno prior Q1 2023 on file
Net Income-$42.39M-$42.39M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.47-$0.47 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$45,257,000N/M
Operating Cash Flowderived-$40,821,000N/M
Free Cash Flowderived-$42,797,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|
| Revenue | $0.00 | — | — |
| Net Income | -$42.39M | -$29.35M | $616.00K |
| EPS Diluted | -$0.47 | -$1.76 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR